Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyPremera Bluecross Omalizumab Coverage Update | Ope…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.513

    Omalizumab products (Xolair, Omlyclo) coverage

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.513 alerts

    Get alerted when Policy 5.01.513 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, site-of-service review, and coverage criteria for omalizumab products (Xolair and Omlyclo) across indications including moderate-to-severe persistent asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy; applies to providers submitting medical or pharmacy benefit requests.

    Policy Summary
    PayerPremera Bluecross
    PolicyOmalizumab products (Xolair, Omlyclo) coverage
    Policy CodePolicy 5.01.513
    Change TypeCoverage and operational updates (authorization length, CIU dosing limit, concurrent biologic restrictions)
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionObtain prior authorization and reference the appropriate omalizumab dosing table (pre-treatment total serum IgE and body weight for asthma; fixed 150 or 300 mg q4w for CIU).
    SourceLink
    POLICY UPDATE CHANGES

    Updated initial authorization for all reviews from 6 months to 12 months.

    Added Exdensur (depemokimab-ulaa) to the list of medications not to be used concurrently with omalizumab for the treatment of asthma.

    Updated chronic idiopathic urticaria (CIU) dose limit to 600 mg every 2 weeks.

    Updated asthma coverage criteria to use maximum tolerated doses of an inhaled corticosteroid instead of maximum doses.

    Removed requirement that adults be non-smokers or enrolled in a smoking cessation program for asthma indication.

    Included treatment of certain individuals with IgE-mediated food allergies in the coverage criteria.

    Policy title updated from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.

    Updated chronic rhinosinusitis with nasal polyps (CRSwNP) criteria to clarify diagnostic requirements and prior systemic corticosteroid or prior surgery requirements.

    Updated chronic idiopathic urticaria criteria to remove prior combination therapy requirement and added restrictions on concurrent use with Dupixent and remibrutinib (Rhapsido).

    Asthma criteria updated to remove the adult non-smoker requirement and to add additional exacerbation-based diagnostic options and FEV1/FVC < 0.80 as an option.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsStandard initial authorization length
    600 mg q2wCIU dose limit
    4Indications with explicit criteria
    J2357, Q5154HCPCS codes listed
    ≥96%Reduction in free IgE (pivotal dosing)

    Coverage Criteria and Indication-Specific Requirements

    Moderate to severe persistent asthma (site-of-service criteria noted)

    Covered when ALL of the following are met

    ALL of the following

    • age: The individual is aged 6 years or olderage >=6
    • controller therapy: Using maximum tolerated doses of an inhaled corticosteroid

      Policy updated to require maximum tolerated dose rather than absolute maximum dose (2025 update).

    • LABA: Using an inhaled long-acting beta-agonist (LABA)
    • Meets ONE of

      • Two or more asthma exacerbations in the previous 12 months requiring use of oral corticosteroids
      • One or more asthma exacerbations requiring hospitalization, emergency department, or urgent care visit in the previous 12 months
      • Forced expiratory volume in 1 second (FEV1) < 80% predictedFEV1 <80% predicted
      • FEV1/forced vital capacity (FVC) < 0.80FEV1/FVC <0.80
      • Asthma that worsens upon tapering of oral corticosteroid therapy (dependence or inability to taper)
    • IgE level: Total serum IgE 30–1,300 IU/mL for ages 6–12 OR 30–700 IU/mL for ages ≥12

      Used with body weight to determine asthma dosing per dosing tables.

    • allergen test: Positive skin test or RAST (serum specific IgE) to a perennial aeroallergen (e.g., dust mite, cockroach, dog, cat, molds)
    • weight: Weight between 20 kg and 150 kg20-150 kg
    • dosing limit: Dose limited to 750 mg every 4 weeks based on serum IgE and body weight dosing table
    • concomitant therapy exclusion: Not used in combination with specified biologics when used for treatment of asthma (Cinqair/reslizumab, Dupixent/dupilumab, Exdensur/depemokimab-ulaa, Fasenra/benralizumab, Nucala/mepolizumab, Tezspire/tezepelumab)

      List expanded in policy updates; concurrent use may trigger denial.

    • prescriber: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist

    ALL of the following

    • site-of-service review: Site-of-service administration review applies per policy (applies to injection drugs and affects where administration is considered medically necessary)

      Added in 2025; see site-of-service criteria for denial triggers.

    ALL of the following

    • authorization length: Prior authorization is required; initial authorization may be approved up to 12 months when medical necessity criteria are met and clinical response is documented12 months

      Initial authorization length updated from 6 to 12 months (2026 update).

    Severe chronic idiopathic urticaria

    Covered when ALL of the following are met

    ALL of the following

    • age: The individual is aged 12 years or olderage >=12
    • exclude other causes: No evidence of another cause of the urticarial reaction
    • duration: At least 6 weeks of symptoms (chronic urticaria, itching, hives, or angioedema)
    • antihistamine failure: Failed or intolerant to at least 2 H1-antihistamines at high doses (at least twice normal dosing and up to 4x normal dosing) or maximum tolerated dose

    Chronic rhinosinusitis with nasal polyps (CRSwNP)

    Covered when ALL of the following are met

    ALL of the following

    • age: The individual is aged 18 years or olderage >=18
    • symptom criteria: Has at least 2 of: facial pressure or pain; moderate–severe nasal congestion, discharge, or obstruction; significant loss of smell
    • IgE: Pretreatment total serum IgE at least 30 IU/mL

      Used with body weight to determine dosing when applicable.

    • weight: Weight between 30 kg and 150 kg

    IgE-mediated food allergy

    Covered when ALL of the following are met

    ALL of the following

    • age: The individual is aged 1 year or olderage >=1
    • diagnosis: Diagnosis demonstrated by ALL: signs/symptoms of a significant systemic allergic reaction shortly after known ingestion of one or more foods AND a positive skin prick test OR positive serum specific IgE to one or more foods
    • concomitant therapy: Medication will be used in conjunction with a diet that avoids the food allergens
    • combination exclusion: Medication will not be used concomitantly with Palforzia (peanut allergen powder)

    Investigational/Not covered indications

    ALL of the following

    • investigational list: Omalizumab products are considered investigational for other uses not listed including allergic rhinitis, atopic dermatitis, other IgE-mediated allergic conditions not listed, latex allergy, bullous pemphigoid

      Policy lists these conditions as investigational/uncovered.

    Maintenance Therapy of Asthma (general coverage basis)

    Covered when ALL of the following are met (as supported by rationale and trial inclusion):

    ALL of the following

    • population: Individual has moderate to severe persistent asthma inadequately controlled despite optimized standard therapy (inhaled corticosteroid plus usually a LABA and other controllers as clinically indicated)

      Policy and rationale support use as add-on therapy in inadequately controlled individuals.

    • individualized treatment: Treatment is individualized consistent with guidelines and trial populations
    • supporting evidence: Pivotal trials demonstrated reduction in exacerbations and healthcare utilization in individuals inadequately controlled on standard therapies

    Chronic Idiopathic Urticaria (CIU)

    Covered for Chronic Idiopathic Urticaria when ALL of the following trial-like criteria are present:

    ALL of the following

    • UAS7: Weekly Urticaria Activity Score (UAS7) ≥16UAS7 >=16

      Per CIU pivotal trials entry requirement.

    • itch severity: Weekly itch severity score ≥8 for the 7 days prior to treatment initiationweekly itch >=8

      Per CIU trials; demonstrates severe disease despite antihistamine use.

    • antihistamine background: Symptoms persist despite use of an H1 antihistamine at an approved dose for at least 2 weeks

    Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    Covered for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) when ALL of the following trial-like criteria are present:

    ALL of the following

    • NPS and NCS: Endoscopic nasal polyp score (NPS) total ≥5 with NPS ≥2 in each nostril AND weekly average nasal congestion score (NCS) >1 despite use of nasal mometasone during run-inNPS >=5 with >=2 per nostril; mean NCS >1

      Matches entry criteria used in pivotal CRSwNP trials.

    • background nasal steroid: Required background nasal mometasone during run-in and treatment periods

      Trials required background intranasal steroid use.

    • diagnosis confirmation: Bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy

    IgE-Mediated Food Allergies

    Covered for IgE-mediated Food Allergies in contexts matching trial populations when ALL are present:

    ALL of the following

    • trial population: Individuals allergic to peanut and at least two other foods studied in the OUtMATCH trial and treated per the trial design to facilitate food challenge tolerance

      Efficacy evidence derives from the NIAID-sponsored OUtMATCH randomized trial (pediatric-dominant population).

    • use context: Medication used to reduce Type I allergic reactions and facilitate oral food challenge/tolerance protocols in conjunction with avoidance diet and clinical monitoring

      Open-label extension provided limited longer-term data; adult effectiveness supported by extrapolation from pediatric data.

    Coverage-related policy updates and indication constraints

    Policy updates and indication-specific requirements noted in the rationale and update history

    Concurrent biologic use: Omalizumab must not be used concurrently with specified biologics for asthma or nasal polyps (e.g., Tezspire/tezepelumab, Dupixent/dupilumab, Exdensur/depemokimab-ulaa)

    List of prohibited concurrent biologics expanded in 2024 and 2026 updates.

    Authorization length: Initial authorization for omalizumab therapies is 12 months for all reviews12 months

    Updated from 6 months in 2026 update.

    CIU dosing limit: Chronic idiopathic urticaria dosing limited to 600 mg every 2 weeks<=600 mg q2w

    Added/clarified in 2026 update.

    Dosing-based coverage for asthma and CIU

    Covered when dosing and documentation meet indication-specific requirements

    Asthma dosing determination: For asthma, dose and dosing interval must be determined from pre-treatment total serum IgE (IU/mL) and body weight using the dosing tables (2‑ or 4‑week schedules); specific mg dosing varies by IgE/weight bandsSee dosing tables (chunks 66-71)

    Do not use IgE measured during ongoing therapy for dose determination; if treatment interrupted <1 year use baseline IgE; if interrupted ≥1 year re-test total serum IgE; adjust doses for significant body weight changes.

    CIU dosing: For chronic idiopathic urticaria, administer 150 mg or 300 mg subcutaneously every 4 weeks; dosing independent of serum IgE or body weightFixed dosing: 150 or 300 mg q4w

    Duration not definitively evaluated; periodically reassess need for continued therapy and document chosen dose and rationale.

    Chronic Idiopathic Urticaria (CIU)

    Coverage applies when individuals meet the indication-specific criteria and prior therapy/diagnostic requirements described in policy.

    ALL of the following

    • CIU dosing: Administer Xolair 150 mg or 300 mg subcutaneously every 4 weeks; dosing is not dependent on serum IgE or body weightevery 4 weeks

      Document dosing chosen (150 vs 300 mg) and rationale; prior authorization updated to 12 months.

    • prior antihistamine trials: Document failure or intolerance to at least 2 H1 antihistamines at high doses or maximum tolerated dose prior to initiation

      Per CIU step therapy requirement.

    IgE-based Dosing Guidance

    Dose determination rules for asthma and other indications where IgE-based dosing applies:

    ALL of the following

    • IgE testing and timing: Total serum IgE levels are elevated during treatment and remain elevated for up to one year after discontinuation; re-testing during treatment cannot be used for dose determination1 year

      If treatment interrupted <1 year use the original baseline IgE for dosing; if interrupted ≥1 year re-test total serum IgE for dosing.

    • weight changes: Adjust doses for significant changes in body weight according to dosing tables

    Moderate to Severe Persistent Asthma

    Asthma and other indication eligibility updates (summary of recent criteria changes):

    Asthma diagnostic options: Individual meets one or more of: ≥2 exacerbations in prior 12 months requiring oral corticosteroids; ≥1 exacerbation requiring hospitalization/ED/urgent care in prior 12 months; FEV1 <80% predicted; dependence on oral corticosteroids or asthma that worsens upon tapering; or FEV1/FVC <0.80

    Policy removed adult non-smoker requirement (2024) and updated ICS criterion to maximum tolerated dose (2025).

    Omalizumab products (Xolair and Omlyclo) are considered investigational for uses not specifically listed as covered in this policy. Examples of investigational or not-covered indications include allergic rhinitis, atopic dermatitis, other IgE-mediated allergic conditions not listed, latex allergy, and bullous pemphigoid. Requests for these indications should be denied as not medically necessary per the policy's investigational exclusions.

    Clinical trial evidence for chronic idiopathic urticaria (CIU) showed benefit for the 150 mg and 300 mg subcutaneous doses administered every 4 weeks; the 75 mg dose did not demonstrate consistent efficacy in the randomized trials and is not an approved dose for CIU.

    The policy prohibits concurrent use of omalizumab with certain other biologic therapies for asthma or nasal polyps. Over successive updates the list of excluded biologics has expanded and now includes agents such as tezepelumab, dupilumab, and the recently added Exdensur (depemokimab-ulaa). Requests for concurrent administration for the same indication may be denied.

    Total serum IgE values rise during omalizumab treatment and may remain elevated for up to one year after discontinuation. Therefore, do not determine or adjust omalizumab dose using total serum IgE levels measured during ongoing treatment; such in-treatment IgE testing is not a valid basis for dosing decisions.

    Concurrent use of omalizumab with other listed biologics (for example Dupixent/dupilumab, Tezspire/tezepelumab, Cinqair/reslizumab, Fasenra/benralizumab, Nucala/mepolizumab, and newly added agents such as Exdensur/depemokimab-ulaa, or investigational agents like remibrutinib) for the same indication is restricted by this policy and may render the request not medically necessary.

    Site-of-service review applies to administration of omalizumab products. When the policy's site-of-service criteria are not met, hospital-based outpatient settings or other higher-cost sites for infusion and injectable therapy services are considered not medically necessary. Preferred medically necessary sites include the physician's office, infusion centers, and home infusion when those criteria are satisfied.

    Use of omalizumab is supported only for individuals who meet the indication-specific, trial-like entry criteria and who remain inadequately controlled despite optimized standard therapies. For asthma, prior documentation should show inadequate control on appropriate controller regimens (e.g., inhaled corticosteroids plus other controllers) and meet the policy's exacerbation or lung function thresholds; use outside these trial-like contexts is not supported.

    The policy sets a maximum CIU dosing limit that must be followed: requests that exceed a total dose of 600 mg every 2 weeks are not supported by this update and may be denied.

    The dosing tables include explicit DO NOT DOSE entries for certain very high pre-treatment total serum IgE and weight combinations (for example, specific bands >900 IU/mL with certain weight ranges). These combinations are considered ineligible per the dosing table and should not be dosed.

    Re-testing total serum IgE during ongoing omalizumab treatment is not acceptable for dose determination because total IgE remains elevated during treatment and for up to one year after discontinuation. If treatment is interrupted for less than 1 year, the original baseline IgE used for initial dosing should be used; only after an interruption of 1 year or more should total serum IgE be re-measured to guide dose selection.

    Coding, Dose Limits, and Key Numeric Parameters

    Covered HCPCS CodesHCPCSCovered
    J2357Injection, omalizumab (Xolair), 5 mg
    Q5154Injection, omalizumab-igec (Omlyclo), biosimilar, 5 mg (new code effective 10/01/25)
    Product coding (refer to PI)NDC
    NDCs referenced in prescribing informationSee Xolair and Omlyclo prescribing information listed in references for product-specific NDCs and formulations.
    Covered HCPCS Codes (specific code for Xolair)HCPCSCovered
    J2357Injection, omalizumab, 5 mg
    Total serum IgE ranges by age (used for dosing tables)
    Age-specific IgE range (ages 6–12)Total serum IgE 30 IU/mL to 1,300 IU/mL
    Age-specific IgE range (ages ≥12)Total serum IgE 30 IU/mL to 700 IU/mL
    PurposeUsed as pre-treatment input with body weight to determine omalizumab dose and dosing interval for asthma dosing tables
    Dose limits — Up to 750 mg every 4 weeks for asthma; up to 600 mg every 2 weeks for urticaria, CRSwNP, and IgE-mediated food allergy (per policy dosing limits)
    Asthma dose capDose limited to 750 mg every 4 weeks (based on serum IgE and body weight dosing table)
    CIU/CRSwNP/IgE-mediated food allergy dose cap

    Prior Authorization, Documentation, and Operational Requirements

    Prior Authorization

    Prior authorization required; approvals up to 12 months

    Prior authorization is required for omalizumab product requests; initial and reauthorization approvals may be granted up to 12 months when medical necessity criteria are met and clinical response is documented.

    • Reauthorization for asthma, CIU, CRSwNP, and IgE‑mediated food allergy may be approved up to 12 months if medical necessity and positive clinical response are documented (e.g., reduced steroid use, fewer exacerbations, improved symptoms or quality of life).
    Prior Authorization

    Confirm inadequate control on standard therapy

    Prior authorization must document inadequate control despite standard controller therapies (for asthma, e.g., use of maximum tolerated inhaled corticosteroid plus long‑acting beta‑agonist and other controllers) before omalizumab is authorized.

    • Confirm trials of optimized inhaled corticosteroid therapy (maximum tolerated dose) and usually a LABA, plus other controllers as appropriate.

    Background, Mechanism, and Evidence Summary

    Omalizumab (Xolair and biosimilar Omlyclo) is a recombinant, humanized anti-IgE monoclonal antibody indicated as add-on therapy in patients with severe allergic asthma not controlled on inhaled corticosteroids and other controllers, for chronic spontaneous urticaria refractory to antihistamines, for inadequately controlled chronic rhinosinusitis with nasal polyps, and to reduce Type I allergic reactions in certain IgE-mediated food allergy contexts. Its pharmacodynamic effect includes a rapid reduction in free IgE (approximately ≥96% reduction with recommended dosing) and total IgE increases due to complex formation; total IgE may remain elevated for up to one year after treatment discontinuation.

    Definitions and Key Terms

    IgE-mediated food allergy — definition and clinical examples
    DefinitionAn allergic condition in which IgE antibodies to specific foods trigger rapid systemic allergic reactions (e.g., hives, swelling) upon exposure
    Diagnostic supportDiagnosis supported by history of significant systemic reaction shortly after known ingestion plus positive skin prick or serum IgE test
    Management notePolicy requires concomitant avoidance diet and prescription of an epinephrine auto-injector when omalizumab used for food allergy
    Site of Service (SOS) — definition and examples
    DefinitionSite of service (SOS) is the location where the drug is administered (hospital outpatient, infusion center, physician's office, or home)
    Policy application

    Policy Updates and Material Changes

    2026-07-14policy_revisionLatest

    Initial authorization period for all omalizumab product reviews updated from 6 months to 12 months; reference to non-formulary exception reviews removed.

    2026-07-14clinical_revision

    Chronic idiopathic urticaria (CIU) dose limit added/updated to 600 mg every 2 weeks.

    2026-07-14clinical_revision
    Policy Summary
    PayerPremera Bluecross
    PolicyOmalizumab products (Xolair, Omlyclo) coverage
    Policy CodePolicy 5.01.513
    Change TypeCoverage and operational updates (authorization length, CIU dosing limit, concurrent biologic restrictions)
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionObtain prior authorization and reference the appropriate omalizumab dosing table (pre-treatment total serum IgE and body weight for asthma; fixed 150 or 300 mg q4w for CIU).
    SourceLink
    On This Page
    Coverage Criteria and Indication-Specific RequirementsCoding, Dose Limits, and Key Numeric ParametersPrior Authorization, Documentation, and Operational RequirementsBackground, Mechanism, and Evidence SummaryDefinitions and Key TermsPolicy Updates and Material Changes

    Policy requires step therapy before omalizumab for CIU.

  1. concomitant antihistamine: Plans to continue treatment with a low dose of H1 antihistamines during omalizumab therapy
  2. combination exclusion: Medication will not be used in combination with Dupixent (dupilumab) or Rhapsido (remibrutinib) for chronic urticaria

    Concurrent use restricted per 2025/2026 updates.

  3. dose limit: Dose limited to 600 mg every 2 weeks

    CIU dose limit added/clarified in 2026 update; 75 mg dose did not demonstrate consistent efficacy and is not approved.

  4. prescriber: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist (or dermatologist as appropriate)
  5. 30-150 kg
  6. diagnosis confirmation: Inadequately controlled bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy
  7. intranasal steroid trial: Tried and had inadequate response or intolerance to intranasal corticosteroid monotherapy
  8. combination: Medication prescribed in combination with an intranasal corticosteroid

    Background nasal mometasone required in trials.

  9. One of

    • Prior systemic corticosteroid use to treat nasal polyps in the last 2 years
    • Contraindication to systemic corticosteroid therapy
    • Previous surgical removal of bilateral nasal polyps (bilateral polypectomy)
  10. dose limit: Dose limited to 600 mg every 2 weeks based on serum IgE and body weight dosing table
  11. combination exclusion: Medication will not be used in combination with Dupixent (dupilumab), Nucala (mepolizumab), or Tezspire (tezepelumab) for CRSwNP

    Concurrent use restricted per updates.

  12. prescriber: Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist (ENT)
  13. epinephrine: Individual has been prescribed an epinephrine auto-injector
  14. dose limit: Dose limited to 600 mg every 2 weeks based on serum IgE and body weight dosing table

    Dose cap aligns with prescribing information and 2026 policy updates.

  15. prescriber: Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist (ENT)
  16. Required run-in condition in CIU trials.

  17. efficacious doses: Clinical trial efficacy demonstrated for 150 mg and 300 mg doses; 75 mg did not demonstrate consistent efficacy

    Policy excludes 75 mg as effective dose.

  18. Asthma severity criteria: Moderate to severe persistent asthma includes: ≥2 exacerbations in prior 12 months requiring oral corticosteroids; or ≥1 exacerbation requiring hospitalization/ED/urgent care in prior 12 months; or FEV1 <80% predicted; or dependence on systemic corticosteroids or asthma that worsens when tapering systemic corticosteroids; FEV1/FVC <0.80 is an alternative option

    Diagnostic options updated in 2024–2025 updates.

    CRSwNP prior treatments: For CRSwNP, diagnosis must be confirmed and patient must have prior systemic corticosteroid use in last 2 years, a contraindication to systemic corticosteroids, or prior bilateral nasal polypectomy

    Clarified in 2025 updates.

    Dose limited to 600 mg every 2 weeks (based on serum IgE and body weight dosing table)
    Policy scopeDose limits apply per the dosing tables and are enforced across omalizumab products in this policy
    Weight ranges used for dosing selection (Asthma: 20–150 kg; CRSwNP: 30–150 kg)
    Asthma weight range20 kg to 150 kg
    CRSwNP weight range30 kg to 150 kg
    PurposeWeight used with pre-treatment total serum IgE to select mg dose and dosing interval from dosing tables
    High Dose Inhaled Corticosteroid definitions (agent- and formulation-specific thresholds)
    DefinitionHigh-dose inhaled corticosteroid defined by agent- and formulation-specific thresholds (examples provided per agent and formulation)
    Example — Beclomethasone HFAHigh dose >320 mcg per day
    Example — Budesonide DPIHigh dose >720 mcg per day
    FEV1 criterion — <80% predicted
    FEV1 thresholdFEV1 < 80% predicted
    ContextIncluded as one of the 'meets one of' asthma severity/exacerbation criteria for moderate to severe persistent asthma
    Supporting noteUsed to demonstrate inadequate lung function despite controller therapy
    FEV1/FVC criterion — <0.80
    FEV1/FVC thresholdFEV1/FVC < 0.80
    ContextAdded as an option in asthma coverage criteria to meet exacerbation/severity requirements
    PurposeAlternative spirometric marker for airflow obstruction consistent with policy asthma definitions
    Pre-treatment total serum IgE and body weight — numerous bands paired with weight ranges used to select dose and frequency (see dosing tables)
    Dosing inputsPre-treatment total serum IgE (IU/mL) combined with body weight (kg) determine mg dose and 2- or 4-week administration frequency
    Multiple bandsDosing tables contain numerous IgE bands (e.g., 30–100, 100–200, 200–300 IU/mL, etc.) paired with weight columns to select dose
    Frequency optionsSpecified doses map to either every 2-week or every 4-week schedules per table cells
    CIU dosing interval — every 4 weeks
    CIU dosing intervalEvery 4 weeks
    CIU dose optionsFixed dosing of 150 mg or 300 mg subcutaneously every 4 weeks
    IgE/weight independenceCIU dosing is not dependent on serum IgE or body weight
    Prior Authorization

    Prior authorization with 12‑month initial approval

    Prior authorization requests must reference that initial approval length is 12 months for all reviews as specified in the policy.

    • The 2026 update set initial authorization for all reviews to 12 months and removed prior references to non‑formulary exception review durations.
    Prior Authorization

    Reference dosing table (IgE + weight) on PA requests

    Prior authorization requests for asthma (and other IgE‑based indications) must reference the appropriate omalizumab dosing table using pre‑treatment total serum IgE and body weight; CIU requests should reference fixed 150 mg or 300 mg q4w dosing tables where applicable.

    • For asthma: include pre‑treatment total serum IgE (IU/mL) and current body weight to select mg dose and 2‑ or 4‑week administration frequency from the dosing tables.
    • For CIU: document selection of 150 mg or 300 mg SC every 4 weeks per dosing guidance.
    Prior Authorization

    Initial authorization period updated to 12 months

    Initial prior authorization period for omalizumab product reviews has been updated to 12 months for all reviews per the 2026 policy update.

    • This change applies to all omalizumab product authorizations effective in the 2026 update.
    Step Therapy

    CIU step therapy: failed ≥2 high‑dose H1 antihistamines

    For chronic idiopathic urticaria, prior authorization requires documentation of failure or intolerance to at least two high‑dose H1‑antihistamines (up to 4× normal dosing or maximum tolerated dose) before starting omalizumab.

    • Policy expects continuation of a low‑dose H1 antihistamine during omalizumab therapy.
    Note

    Policy supports omalizumab as add‑on for uncontrolled disease

    Policy language supports using omalizumab as an additional option for individuals not controlled with inhaled corticosteroids and other controller therapy when criteria are met.

    • Omalizumab is considered an add‑on after optimization of standard asthma controller regimens.
    Prior Authorization

    Document required prior therapies per indication

    Prior authorization must document prior trials of standard therapies where specified by indication (e.g., CIU refractory to high‑dose H1 antihistamines; CRSwNP with prior systemic corticosteroid use or prior bilateral polypectomy or contraindication).

    • For CRSwNP: document prior systemic corticosteroid use within 2 years, contraindication to systemic corticosteroids, or prior bilateral nasal polyp surgery per criteria.
    Documentation Required

    Document background controller therapy trials

    Provider should recognize omalizumab is add‑on therapy to standard asthma controller medications; the appendix lists inhaled corticosteroids, long‑acting bronchodilators, leukotriene modifiers, and oral corticosteroids as background controller options.

    • Include history of use/intolerance of listed controller agents when submitting PA for asthma.
    Prior Authorization

    Indication‑specific prior therapy requirements

    For CRSwNP and CIU, prior use of specific therapies or documented inadequate response may be required (e.g., prior systemic corticosteroids or prior sinus surgery for CRSwNP; for CIU prior high‑dose antihistamine steps).

    • CRSwNP: document diagnosis of inadequately controlled bilateral disease and prior systemic steroid use in last 2 years or prior bilateral polypectomy or contraindication to systemic steroids.
    • CIU: document failure/intolerance of ≥2 H1 antihistamines at high doses.
    Documentation Required

    Required medical record documentation

    Medical records submitted for review must document that medical necessity criteria are met and include office visit notes with diagnosis, relevant history, physical exam, and medication history.

    • Include chart notes that demonstrate baseline disease status and subsequent clinical response for reauthorization.
    Documentation Required

    Document trial‑like entry criteria (NPS, UAS7)

    Document disease‑specific entry criteria used in clinical trials when applicable — for CRSwNP include endoscopic nasal polyp score (NPS) total ≥5 with ≥2 in each nostril and mean nasal congestion score >1 despite nasal mometasone; for CIU document UAS7 ≥16 and weekly itch ≥8 despite antihistamine therapy.

    • Attach endoscopy or scoring documentation and symptom scores from the run‑in period where available.
    Documentation Required

    Document dosing per FDA prescribing information

    Document that dosing and administration follow the product's FDA prescribing information and record prior use/trials of therapies required by specific indication criteria.

    • Include reference to the prescribing information dosing tables when indicating dose selection.
    Documentation Required

    Document dosing choice and re‑testing after interruption ≥1 year

    Document the dosing chosen and rationale (e.g., 150 mg vs 300 mg for CIU); if treatment was interrupted ≥1 year, include repeat total serum IgE testing for asthma dose determination.

    • For interruptions <1 year, state rationale to use original pre‑treatment IgE for dose determination; for ≥1 year, provide new serum IgE result.
    Documentation Required

    Required documentation of dosing regimen and IgE when interrupted

    For dosing after treatment interruptions under 1 year, document the original pre‑treatment total serum IgE used to determine dose; for interruptions of one year or more, provide repeat total serum IgE for dose determination.

    • Also document any significant weight change that would alter dose selection from the dosing tables.
    Denial Risk

    Site‑of‑service denial triggers and SOS rules

    Site‑of‑service requests may be denied if site‑of‑service criteria are not met (preferred outpatient sites, first‑90‑days rule, availability within 50 miles, contracted home infusion, or clinical risk criteria); hospital‑based outpatient infusion considered not medically necessary when criteria are unmet.

    • Hospital outpatient setting is medically necessary for the first 90 days for initial course or re‑initiation after ≥6 months only when criteria are met.
    • If no outpatient infusion center within 50 miles and no contracted home infusion, hospital setting may be considered medically necessary.
    Denial Risk

    Denial risk if inadequate control on maximal therapy not shown

    Lack of documented inadequate control on maximal/optimized therapy for asthma may undermine PA justification; pivotal trials showed benefit primarily in individuals inadequately controlled despite inhaled corticosteroids and other controllers.

    • Ensure documentation of exacerbation history, FEV1/FEV1‑FVC data, steroid dependence, or other listed severity markers to support need for omalizumab.
    Denial Risk

    Denial triggers: dose limits and prohibited concurrent biologics

    Requests exceeding the chronic idiopathic urticaria dose limit (600 mg every 2 weeks) or requests for concurrent use with listed biologics (including newly added Exdensur/depemokimab‑ulaa) may be denied.

    • Policy explicitly limits CIU dosing to 600 mg q2w; concurrent use with specified biologics for asthma/nasal polyps is prohibited.
    Documentation Required

    IgE testing timing: do not use in‑treatment IgE for dosing

    Do not use serum total IgE levels obtained during ongoing omalizumab treatment for dose determination because total IgE is elevated during and up to one year after treatment.

    • If dose determination requires IgE and treatment was interrupted <1 year, use the original pre‑treatment IgE; re‑test only if interruption ≥1 year.
    Denial Risk

    Combination therapy restrictions: no concurrent biologics

    Concurrent use of omalizumab with listed biologics (e.g., Tezspire, Dupixent, Exdensur, remibrutinib and others identified in policy) for the same indication is restricted and can trigger denial.

    • When submitting PA, state that omalizumab will not be used concurrently with the named biologic therapies for the same condition.
    Documentation Required

    IgE re‑testing limitation for dose determination

    Re‑testing total serum IgE during ongoing Xolair treatment is not acceptable for dose determination unless treatment was interrupted for one year or longer; using in‑treatment IgE to set dose may lead to denial.

    • Document the timing of any treatment interruption and provide either original baseline IgE (if <1 year) or a new IgE (if ≥1 year) per dosing guidance.
    Site-of-service medical necessity review applies for administration locations and to members age 13 years and older
    ExamplesHospital-based outpatient setting, infusion center, physician office, or home administration
    Omalizumab (Xolair) — drug definition/mechanism
    Drug class/mechanismOmalizumab is a recombinant humanized anti-IgE monoclonal antibody that inhibits IgE binding to the high-affinity IgE receptor (FcεRI)
    Pharmacologic effectReduces surface-bound IgE on effector cells and downregulates FcεRI expression
    Products coveredXolair (omalizumab) and biosimilar Omlyclo (omalizumab-igec) are included under this policy
    UAS7 — Weekly urticaria activity score definition
    Score name and rangeUAS7 — Weekly urticaria activity score, range 0 to 42
    ComponentsComposite of weekly itch severity (0–21) plus weekly hive count (0–21)
    Trial entry thresholdCIU pivotal trials required UAS7 ≥16 and weekly itch severity ≥8 at baseline
    NPS — Nasal Polyp Score definition
    DefinitionNPS (Nasal Polyp Score) measured endoscopically: 0–4 per nostril, total range 0–8
    Trial requirementCRSwNP trials required total NPS ≥5 with NPS ≥2 in each nostril
    Scoring examples0 = no polyps; 4 = large polyps causing complete obstruction of inferior nasal cavity
    Pharmacodynamic effect — reduction in serum-free IgE (~96%)
    Magnitude of effectDosing per total serum IgE and body weight reduces serum-free IgE by approximately 96% within one hour
    Clinical relevanceRapid reduction in free IgE underlies the therapeutic effect in allergic conditions treated with omalizumab
    SourceReferenced in FDA labeling and prior rationale sections
    Moderate to severe persistent asthma (policy definition) — updated clinical definition and markers
    Policy definitionModerate to severe persistent asthma includes prior exacerbations and markers such as FEV1 <80% predicted, FEV1/FVC <0.80, dependence on or worsening with tapering oral corticosteroids, or recent exacerbations requiring systemic steroids or hospitalization
    Age criterionIndication applies to individuals aged 6 years or older per policy criteria
    Treatment contextIntended for individuals inadequately controlled despite maximum tolerated inhaled corticosteroid and LABA therapy
    Chronic Idiopathic Urticaria (CIU) — definition and dosing notes
    DefinitionChronic Idiopathic Urticaria (CIU) is chronic spontaneous urticaria treated with omalizumab 150 or 300 mg SC every 4 weeks
    Dosing noteCIU dosing is fixed (150 or 300 mg q4w) and is not based on serum IgE or body weight; 75 mg did not demonstrate consistent efficacy
    Trial contextEfficacy demonstrated in randomized trials requiring UAS7 ≥16 and weekly itch ≥8 despite H1 antihistamine therapy
    Pre-treatment total serum IgE — definition and role in dosing
    RolePre-treatment total serum IgE is the baseline IgE (IU/mL) used with body weight to determine omalizumab dose and dosing interval for asthma prior to initiating therapy
    Timing limitationDo not use IgE levels obtained during ongoing treatment to determine dose because total IgE is elevated during treatment and up to one year after discontinuation
    Re-testing ruleIf treatment interrupted ≥1 year, re-test total serum IgE for dose determination; if interruption <1 year, use initial baseline IgE
    Dose determination after interruption — rule for re-testing after ≥1 year interruption
    Interruption <1 yearIf treatment was interrupted for less than 1 year, use the original pre-treatment total serum IgE for dose determination
    Interruption ≥1 yearIf treatment was interrupted for one year or more, re-test total serum IgE and use the new value to determine dose
    RationaleTotal IgE rises during treatment and may remain elevated up to one year after discontinuation, invalidating in-treatment IgE for dosing

    Exdensur (depemokimab-ulaa) added to the list of biologics not to be used concurrently with omalizumab for asthma.

    2025-01-03clinical_revision

    Clarified asthma criteria (use of maximum tolerated inhaled corticosteroid doses, addition of FEV1/FVC <0.80 option) and added site-of-service review and CRSwNP prior-treatment requirements.

    2024-01-03clinical_revision

    Removed adult non-smoker requirement for asthma indication and added coverage of certain individuals with IgE-mediated food allergies (effective January 3, 2025 for those updates).